Диссертация (1155054), страница 35
Текст из файла (страница 35)
Tseng, T.S. Santra. – Berlin, Heidelberg:Springer Berlin Heidelberg, 2016. – P. 325-346 doi:10.1007/978-3-662-49118-8_12.218. Shukla S. Anticancer potential of medicinal plants and their phytochemicals: areview / S. Shukla, A. Mehta // Brazilian Journal of Botany. – 2015. – Vol. 38. – № 2.– P. 199-210 doi:10.1007/s40415-015-0135-0.219. Silverman J.A. Marqibo (vincristine sulfate liposome injection) improves thepharmacokinetics and pharmacodynamics of vincristine / J.A.
Silverman, S.R.211Deitcher // Cancer Chemotherapy and Pharmacology. – 2013. – Vol. 71. – № 3. –P. 555-564 doi:10.1007/s00280-012-2042-4.220. Simple and reproducible HPLC–DAD–ESI-MS/MS analysis of alkaloids inCatharanthus roseus roots / F. Ferreres, D.M. Pereira, P. Valentão [et al.] // Journal ofPharmaceutical and Biomedical Analysis. – 2010. – Vol. 51. – № 1. – P. 65-69doi:10.1016/j.jpba.2009.08.005.221.
Simultaneous determination of Vincristine and Vinblastine in Vinca rosea leavesby High Performance Thin Layer Chromatography / K. Abid, A. Sayeed, A.F. Jalees[et al.] // International journal of drug development and reaserch. – 2013. – Vol. 5. –№ 3. – P. 341-348.222. Singh P. Ocular adverse effects of Anti-cancer Chemotherapy / P. Singh, A.Singh // journal of Cancer Therapeutics and Research. – 2012. – Vol. 1.
– № 1. – P. 5doi:10.7243/2049-7962-1-5.223. Skladanowski A. Downregulation of DNA topoisomerase IIalpha leads toprolonged cell cycle transit in G2 and early M and increased survival to microtubuleinteracting agents / A. Skladanowski // Molecular Pharmacology. – 2005. – Vol. 68. –№ 3. – P. 625-634 doi:10.1124/mol.105.013995.224. Smart blood cell and microvesicle-based Trojan horse drug delivery: Mergingexpertise in blood transfusion and biomedical engineering in the field of nanomedicine/ Y.-W. Wu, H.
Goubran, J. Seghatchian [et al.] // Transfusion and Apheresis Science.– 2016. – Vol. 54. – № 2. – P. 309-318 doi:10.1016/j.transci.2016.04.013.225. Snow J.W. Antitubulin Agents: Colchicine, Vinca Alkaloids, and Podophyllin /J.W. Snow, L.W. Kao, R.B. Furbee // Critical Care Toxicology / eds. J. Brent [et al.]. –Cham: Springer International Publishing, 2016. – P. 1-23 doi:10.1007/978-3-31920790-2_138-1.226.
Sprandel U. Erythrocytes as Drug Carriers in Medicine / U. Sprandel, J.L. Way;eds. U. Sprandel, J.L. Way. – Boston, MA: Springer US, 1997. – 149 p.doi:10.1007/978-1-4899-0044-9.212227. Structural basis for the regulation of tubulin by vinblastine / B. Gigant, C. Wang,R.B.G.
Ravelli [et al.] // Nature. – 2005. – Vol. 435. – № 7041. – P. 519-522doi:10.1038/nature03566.228. Studies on the stability of vinblastine sulfate in aqueous solution / J. Black, D.D.Buechter, J.W. Chinn [et al.] // Journal of pharmaceutical sciences.
– 1988. – Vol. 77.– № 7. – P. 630-634.229. Svoboda G.H. The Role of the Alkaloids of Catharanthus Roseus ( L .) G . Don (Vinca Rosea ) and Their Derivatives in Cancer Chemotherapy / G.H. Svoboda //Plants: The Potentials for Extracting Protein, Medicines, and Other Useful Chemicals.– Indianapolis,InD., 1983. – P. 154-169.230. Symmetry C18 column: a better choice for the analysis of indole alkaloids ofCatharanthus roseus / G.C. Uniyal, S.
Bala, A.K. Mathur [et al.] // PhytochemicalAnalysis. – 2001. – Vol. 12. – № 3. – P. 206-210 doi:10.1002/pca.575.231. Synthesis and in Vitro Antitumor Effect of Vinblastine Derivative?OligoarginineConjugates / Z. Ba?no?czi, A. Gorka-Kereske?nyi, J. Reme?nyi [et al.] // BioconjugateChemistry. – 2010. – Vol. 21. – № 11. – P. 1948-1955 doi:10.1021/bc100028z.232. Synthesis and SAR of vinca alkaloid analogues / M.E. Voss, J.M.
Ralph, D. Xie[et al.] // Bioorganic & Medicinal Chemistry Letters. – 2009. – Vol. 19. – № 4. –P. 1245-1249 doi:10.1016/j.bmcl.2008.12.077.233. Szabó L.F. Rigorous Biogenetic Network for a Group of Indole AlkaloidsDerived from Strictosidine / L.F. Szabó // Molecules. – 2008. – Vol. 13. – № 8. –P. 1875-1896 doi:10.3390/molecules13081875.234. Tachihara R. The effect of dacarbazine and vincristine sulfate on humanmelanoma cell lines.
In vitro analysis of interaction on DNA synthesis, RNA synthesisand protein synthesis. / R. Tachihara // Nihon Ika Daigaku zasshi. – 1997. – Vol. 64. –№ 3. – P. 238-48.235. Tam M.N. Quantitative Thin Layer Chromatography of Indole Alkaloids.
II.213Catharanthine and Vindoline / M.N. Tam, B. Nikolova-Damyanova, B. Pyuskyulev //Journal of Liquid Chromatography. – 1995. – Vol. 18. – № 5. – P. 849-858doi:10.1080/10826079508010396.236. Teale J. Radioimmunoassay of vinblastine and vincristine. / J. Teale, J. Clough,V. Marks // British Journal of Clinical Pharmacology. – 1977. – Vol. 4. – № 2.
–P. 169-172 doi:10.1111/j.1365-2125.1977.tb00690.x.237. Tellingen O. van. Analytical methods for the determination of vinca alkaloids inbiological specimens: A survey of the literature / O. van Tellingen, J.H. Beijnen, W.J.Nooyen // Journal of Pharmaceutical and Biomedical Analysis. – 1991. – Vol. 9. –№ 10-12. – P.
1077-1082 doi:10.1016/0731-7085(91)80047-D.238. Terheyden P. New developments in the biology and the treatment of metastaticMerkel cell carcinoma / P. Terheyden, J.C. Becker // Current Opinion in Oncology. –2017. – Vol. 29. – № 3. – P. 221-226 doi:10.1097/CCO.0000000000000363.239. The Catharanthus Alkaloids: Pharmacognosy and Biotechnology / R. van derHeijden, D.I. Jacobs, W.
Snoeijer [et al.] // Current Medicinal Chemistry. – 2004. –Vol. 11. – P. 607-628.240. The Cytoskeleton / B. Alberts, A. Johnson, J. Lewis [et al.] // Molecular Biologyof THE CELL. – NY: Garland Science, Taylor & Francis Group, LLC, 2014. –P. 1465.241. The pharmacokinetics of [3H]-vincristine in man / R.A. Bender, M.C. Castle,D.A. Margileth [et al.] // Clinical Pharmacology and Therapeutics. – 1977. – Vol. 22. –№ 4. – P. 430-438.242.
The synergic effect of vincristine and vorinostat in leukemia in vitro and in vivo /M.-W. Chao, M.-J. Lai, J.-P. Liou [et al.] // Journal of Hematology & Oncology. –2015. – Vol. 8. – № 1. – P. 82 doi:10.1186/s13045-015-0176-7.243. The vinca alkaloids: a new class of oncolytic agents / I.S. Johnson, J.G.Armstrong, M.
Gorman [et al.] // Cancer research. – 1963. – Vol. 23. – № 77. – P.2141390-427.244. Tikhomiroff C. Screening of Catharanthus roseus secondary metabolites by highperformance liquid chromatography / C. Tikhomiroff, M. Jolicoeur // Journal ofChromatography A. – 2002. – Vol. 955. – № 1. – P. 87-93 doi:10.1016/S00219673(02)00204-2.245. Torchilin V.P. Recent advances with liposomes as pharmaceutical carriers / V.P.Torchilin // Nature Reviews Drug Discovery. – 2005.
– Vol. 4. – № 2. – P. 145-160doi:10.1038/nrd1632.246. Transcriptome analysis in Catharanthus roseus leaves and roots for comparativeterpenoid indole alkaloid profiles / A.K. Shukla, A.K. Shasany, M.M. Gupta [et al.] //Journal of Experimental Botany. – 2006. – Vol. 57. – № 14. – P. 3921-3932doi:10.1093/jxb/erl146.247. Transdermal and lymph targeting transfersomes of vincristine / Y. Lu, S. Hou, L.Zhang [et al.] // Yao xue xue bao(eng- Acta pharmaceutica Sinica). – 2007. – Vol. 42.– № 10.
– P. 1097-101.248. Treatment of Kaposi’s sarcoma and thrombocytopenia with vincristine in patientswith the acquired immunodeficiency syndrome / D.M. Mintzer, F.X. Real, L. Jovino[et al.] // Annals of Internal Medicine. – 1985. – Vol. 102. – № 2. – P. 200-202.249. Tsuchida K. Drug Delivery Systems for Cancer Treatment / K. Tsuchida //Encyclopedia of Cancer / ed. M. Schwab. – Elsevier, 2002. – Vol. 1. – P. 1160-1162.250. Tucker S.B. Treatment of Kaposi Sarcoma With Vinblastine / S.B.
Tucker //ArchivesofDermatology.–1976.–Vol. 112.–№ 7.–P. 958doi:10.1001/archderm.1976.01630310020004.251. Turning Erythrocytes into Functional Micromotors / Z. Wu, T. Li, J. Li [et al.] //ACS Nano. – 2014. – Vol. 8. – № 12. – P. 12041-12048 doi:10.1021/nn506200x.252. Updike S.J. Infusion of red blood cell-loaded asparaginase in monkey.Immunologic, metabolic, and toxicologic consequences / S.J. Updike, R.T. Wakamiya215// The Journal of laboratory and clinical medicine. – 1983.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
